Cullinan Therapeutics Inc. (CGEM) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Cullinan Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$15.56
+4.85% today
Market cap
$955M
Overall quality
43/100
Kronos AI 30-day
+7.7%
7 of 8 simulated paths end higher
Cullinan Therapeutics Inc. (CGEM) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $955M. It trades at $15.56, up 4.85% today. Its overall quality score is 43 out of 100, ranked against the whole US market. 11 analysts' average target of $35.80 implies +130.1% from today's price. Kronos AI's 30-day forecast is +7.7% (7 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $35.80 |
| Low – high | $27.00 – $47.00 |
| Analysts | 11 |
| Upside to average | +130.1% |
Kronos AI 30-day forecast
| Expected close | $15.97 (+7.7%) |
| Likely range | +0.9% … +9.6% |
| As of | 2026-10-27 |
7 of 8 simulated paths end higher.
Quality scores
| Profitability | 40 |
| Solvency | 58 |
| Growth | 30 |
| Overall | 43 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.